
Yes, You May Lose Your Job To AI. So What Will You Do About It?
Putting the notion of "AI won't take your job" into context.
The real disruption isn't about individual workers becoming AI-savvy. It's about the obsolescence of entire job categories as AI becomes exponentially more capable, efficient, and effective at core business functions.
The Exponential Reality Check
Here's what should terrify you: Today is the worst AI will ever be.
Several current AI models have surpassed the average IQ of humans. Most people have an average IQ between 85 and 115. Overall, about 98% of people have a score below 130, with the 2% above that are considered 'very superior'.
With the latest versions of OpenAI's o3, Anthropic's Claude 4 Sonnet, and Google's Gemini 2.0 Flash Thinking Experimental all well above average human intelligence scores, we now have genius-level AI.
Ranking The Smartest AI Models by IQ Level
But that's just the beginning. AI capability is roughly doubling every six months. Let's do the math and be a bit more conservative and assume it doubles every year:
I share this just for illustrative purposes. Humans typically think in a linear fashion. It's hard for us to think exponentially. And it's hard to not think this is all 'science fiction' and will happen years in the future. No. This is happening now. This is compound growth in action. When AI can already write better marketing copy than most marketers, analyze data faster than any analyst, and code more efficiently than many developers TODAY - imagine what happens when it's 32 times more capable in just five years.
The Job Container Is Breaking
For decades, companies have organized human effort into neat packages called "jobs"—performing tasks in predefined roles with specific responsibilities, reporting structures, and compensation bands. This industrial-age framework worked when work was predictable, hierarchical, and required sustained human attention.
AI is obliterating this model. When artificial intelligence can write code in minutes, draft legal briefs in seconds, and generate marketing campaigns instantly, traditional job boundaries become arbitrary constraints. Why maintain a "Marketing Manager" role when AI can execute campaigns while a strategic thinker provides direction? Why preserve "Financial Analyst" positions when AI can process datasets that would take humans months to review?
Think this is hype? Check out the latest release that dropped this week from HeyGen, an AI-powered video creation platform that allows users to generate videos with AI avatars, text-to-speech, and customizable templates. They just announced this week the HeyGen Video Agent, the first prompt-native creative engine designed to transform a single idea into a complete, publish-ready video asset. Whether that's a TikTok ad, a YouTube hook, a product explainer, or a quickfire UGC clip, the video is created by AI in seconds. The tool looks amazing, and it will surely be compelling to marketers at small companies to large global enterprises. However, this is another nail in the coffin for a creative agency or production company that was providing those services.
We're entering the era of agentic content creation where intelligent systems don't just assist with ... More editing, but act on your behalf to create high-quality videos, end to end.
Reading Between The Lines: The Amazon Example
The companies that survive won't be those that train existing jobholders to use AI tools. They'll be the ones that completely reimagine how work gets done.
On June 17th, Amazon CEO Andy Jassy published a memo with "Some thoughts on Generative AI." While highlighting AI's incredible applications across the company, he dropped this bombshell:
'As we roll out more Generative AI and agents, it should change the way our work is done. We will need fewer people doing some of the jobs that are being done today, and more people doing other types of jobs. It's hard to know exactly where this nets out over time, but in the next few years, we expect that this will reduce our total corporate workforce as we get efficiency gains from using AI extensively across the company.'
This should be a wake-up call.
It's a direct admission that AI will eliminate jobs, and it should terrify anyone doing repetitive or process-driven work. Amazon is just the latest in a number of companies that are signaling what is to come slowly, carefully, and publicly.
Sure for now it's mostly tech companies like Duolingo, Klarna, and Shopify that are talking about being 'AI first'. In the case of Shopify, CEO Tobi Lütke told employees that teams must demonstrate why AI cannot fulfill a role before requesting to hire a human. This effectively positions AI as the default option for many tasks.
This AI first approach might start in tech, but it won't end there.
The Rise of Liquid Labor
Forward-thinking organizations are moving beyond "jobs" toward what I call 'Liquid Labor'. In a hybrid human-AI workforce, Liquid Labor is the fluid combinations of human creativity, AI capabilities, and automated processes that adapt in real-time to business needs.
Consider Netflix. They don't have traditional "TV Programming Executive" jobs. Instead, they have data scientists, content strategists, and algorithm specialists working in fluid teams that constantly reconfigure based on viewer behavior and market opportunities.
This shift challenges everything:
OK, this is scary. So What Should I Do?
The obvious answer is to upskill yourself and learn how to use all of these AI tools. Are you using not just one model (say ChatGPT), but experiment with multiple models from Claude to Perplexity to CoPilot to Gemini to Grok. They all have their strengths and weaknesses, so learn what works best for you. This is table-stakes, though.
Here's a more candid survival guide:
Double down on uniquely human capabilities that AI can't replicate (yet):
Develop higher-order thinking abilities that allow you to adapt and learn faster than AI can optimize for your replacement, focusing on skills that help you navigate complexity and change rather than specific technical competencies:
Become the critical bridge between AI systems and human needs:
Forge a unique professional identity:
Urgently diversify your income streams and build wealth-generating assets while you still have earning power:
Cultivate deep, value-creating relationships as your unique network of human connections becomes one of your most defensible and irreplaceable assets in the AI era:
The Time to Act Is Now
Most people think they have years to adapt.
They're wrong.
By the time AI visibly threatens your job, it's already too late. The exponential curve means:
The window for repositioning yourself is now, while you still have leverage, income, and options.
The transformation from jobs to liquid labor is already here. The choice isn't between learning AI or losing your job. It's between fundamentally reimagining your career or watching it become obsolete.
Those who act now - building unique capabilities, creating new value propositions, and positioning themselves at the human-AI interface - won't just survive. They'll thrive in ways we can't yet imagine.
Those who wait, believing that disruption is still years away, will discover that no amount of prompt engineering can compete with exponentially improving AI that works 24/7, never gets sick, and improves while you sleep.
The question isn't whether this transformation will affect you, but whether you'll adapt fast enough.
Now is the time to get AI ready.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Pfizer battles another Paxlovid lawsuit from Enanta
If you don't succeed at first, try again – in separate regions. That's the motto Enanta Pharmaceuticals is following, at least, after disclosing it has sued Pfizer in Europe over a patent infringement relating to Covid-19 treatment pill Paxlovid (nirmatrelvir/ritonavir). In June 2022, Enanta filed a lawsuit against Pfizer in a US district court in Massachusetts, claiming that the big pharma company infringed on a patent describing protease inhibitors invented by its scientists. Enanta has now followed that up with another filing in Europe, making the same accusation. Since being emergency authorised in 2021, anti-viral Paxlovid has generated Pfizer more than $26bn in global revenue. This includes a staggering $18.9bn in 2022 when Covid-19 cases were still prevalent. Despite waning demand for Covid-19 treatments, the pill still brought in $1.2bn in 2024, buoyed by government orders. However, Enanta – known for co-developing hepatitis C virus treatment glecaprevir/pibrentasvir with AbbVie – believes Pfizer designed Paxlovid via unlawful means. The US biotech stated it is 'seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's Covid-19 antiviral, Paxlovid'. In an emailed statement to Pharmaceutical Technology, a Pfizer spokesperson said: 'We are confident in our intellectual property (IP) surrounding Paxlovid and will respond in due course in court.' The lawsuit, filed in the European Union's (EU) Unified Patent Court (UPC), targets Pfizer's commercial activity in the 18 countries of the EU. The company confirmed the '265 patent in question is the European counterpart of US patent number 11,358,953 (the '953 Patent) that is the centre of the US lawsuit. Although it is technically ongoing, Enanta's US lawsuit hit a major roadblock. In December 2024, a federal judge in Massachusetts sided with Pfizer, granting that the '953 patent is invalid. Enanta confirmed at the time it would appeal the decision, adding it 'believes strongly in the merits of our case'. Pfizer reported strong Q2 2025 results this month, bucking a tepid earnings window that gripped the wider pharma industry. Sales for the Paxlovid grew 71% while the Covid-19 vaccine Comirnaty revenue surged 95%. However, the legal challenge posed by Enanta marks the second issue Pfizer has had to firefight this week. The big pharma company reported a Phase III trial failure for a sickle cell disease candidate purchased as part of a $5.4bn takeover of Global Blood Therapeutics in 2022. "Pfizer battles another Paxlovid lawsuit from Enanta" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Nasdaq slides again as AI jitters rattle tech investors
NEW YORK (Reuters) -Tech stocks are leading declines on Wall Street, with worries about AI spurring debates about its future. The Nasdaq Composite is down around 2.4% over the last two days, the worst two-day fall since April. The semiconductor index was down 1.5%, while the information technology sector was the second biggest decliner in the S&P 500, dropping 1.1% on Wednesday. Market participants attributed the selloff to a range of factors including a technical pullback after driving much of the stock market's recovery in the weeks after April 2nd "Liberation Day." Analysts also cited deepening concerns of government interference with companies, as the Trump administration looked into taking equity stakes in chip companies such as Intel in exchange for grants under the CHIPS Act. COMMENTS: ART HOGAN, MARKET STRATEGIST, B. RILEY WEALTH MANAGEMENT, BOSTON: "Technology in general is up 40% from its April lows, and the group clearly got ahead of itself. Also, if there's anything to the market consensus that we'll see a Fed rate cut, then there will be room for other things to work as well – and there are 493 other stocks in the S&P 500 that are lagging the Mag 7 right now. So I think there's a bit of a rotation." "I don't know how long it will last, but if it does keep going, well, August and September (are) the weak period seasonally in which it could do so. Also, there are some people who are beginning to question the pace at which we need to be chasing AI capital spending. If you put all this together: when technology stocks take a breather, this is what it looks like. Nvidia and other blue chips in the group are seeing relatively steady drawdowns, but things on the speculative edge are clearly seeing more selling pressure. Palantir has gone from trading at 200 times sales to 150 times its sales, for instance." MICHAEL ASHLEY SCHULMAN, CHIEF INVESTMENT OFFICER, RUNNING POINT, EL SEGUNDO, CALIFORNIA: "Tuesday' s U.S. technology stock swoon and its continuation today looks like multiple compression meeting a little margin math, but the timing makes it hard to ignore the new elephant in the server room. Names that had been sprinting on AI dreams pulled back hard, with Nvidia, AMD, and Palantir Technologies among the drags." "DeepSeek's update landed on Tuesday represents a serious cocktail of capability and availability and traders well remember the original harsh tech-market pullback DeepSeek caused when it was first broadly recognized in January of this year." BRIAN JACOBSEN, CHIEF ECONOMIST, ANNEX WEALTH MANAGEMENT, BROOKFIELD, WISCONSIN: "When you go from rally to rout, it shows how vulnerable the names were to even a scent of bad news. It could have been (Sam)Altman's valuation warning and then Meta restructuring its AI division threw fuel on the fire." PHIL BLANCATO, CHIEF EXECUTIVE OFFICER, LADENBURG THALMANN ASSET MANAGEMENT, NEW YORK: "It's much more about profit-taking and temporary rebalancing here. If you get a Federal Reserve cut or a mention of it on Friday, this will reverse pretty quickly, but this is a lot to do with names pushed up to really lofty levels and profit taking across the board." SETH HICKLE, PORTFOLIO MANAGER, MINDSET WEALTH MANAGEMENT, INDIANAPOLIS: "I think we are starting to see a little bit of rotation. It's always healthy to see a little bit of a pullback to that way, the markets can kind of get re-oriented." "To me, tech was overbought. Maybe it was justified, but it could have been kind of a buy on the rumor, sell it on the news type of thing where we had tech runup into earnings. We had really good earnings, and now it's kind of natural for the market just to sell some of that good news." "I wouldn't be surprised if we see a little bit of rotation into some smaller cap or into healthcare names, or consumer staples. And to me, that's kind of a healthy rotation. But honestly, I don't believe it will be a longer-term trend. It'll probably be a shorter-term trend. I think we'll see money flow back into tech in the next couple months." STEVE SOSNICK, CHIEF STRATEGIST, INTERACTIVE BROKERS, CONNECTICUT "The tech-led selloff that we saw yesterday resumed this morning. That said, dip buyers stepped in around 11am EDT and we've now recovered about half our losses. It's somewhat inevitable to expect them to arrive promptly, though it did take a bit longer than usual." "I believe that some of the early declines are related to profit-taking and risk squaring ahead of (Fed Chair Jerome)Powell's speech on Friday. That is merely rotation and relatively benign, though it gets magnified because of megacap tech stocks' heavy weighting in key indices. But some of the ferocity of the early drop was related to the President's calls for Lisa Cook's resignation." "Note that futures broke through their pre-market lows shortly after he posted on Truth Social. Markets were not perturbed that there are inquiries into the propriety of her personal mortgage applications. She gets a presumption of innocence until proven guilty, like any other person. But when the President weighed in even before the process began, then it raised the specter of politicization. That put markets on the wrong foot early, and negative momentum ruled again – at least for a couple of hours." ADAM SARHAN, CHIEF EXECUTIVE, 50 PARK INVESTMENTS, NEW YORK: "To see a little pullback here after a big move up is perfectly normal and healthy. If the selling gets worse then you'll see a rotation out of tech and into undervalued areas of the market like biotech stocks or healthcare stocks or small cap stocks because those areas have not participated this year." Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
TX RX Systems Launches New 'Deepwave' Antenna Line to Fill Industry Gap
TX RX Systems Deepwave Antennas BUFFALO, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- TX RX Systems, a leader in RF conditioning and communications technology for nearly five decades, has announced the launch of its new Deepwave antenna series. This is a comprehensive product line designed to serve as the next-generation solution for organizations seeking high-performance VHF and UHF omnidirectional antennas similar to those found in now-unavailable legacy lines. Engineered and manufactured on-site in the United States, Deepwave antennas deliver industry-proven performance at a significantly lower cost than comparable offerings currently available in the market. Designed for both mission-critical and commercial applications, the line is suitable for integrators, public safety agencies, utilities, transportation providers, manufacturing facilities, government entities, and any organization requiring durable, broadband RF coverage. The new Deepwave series features wideband coverage across VHF and UHF ranges, allowing flexible deployment across multiple systems and jurisdictions. Models are available with nominal gains ranging from 3 dBd to 9 dBd, providing consistent coverage and minimal distortion throughout the entire operating band. Low VSWR, typically 1.5:1 or less across the specified frequency range, ensures efficient power transfer and reduced reflected power. Each antenna is designed to handle high transmit power levels, making them ideal for both high-site and dense urban installations. Durability is a core design priority for the Deepwave line. Heavy-duty fiberglass radomes and stainless steel hardware protect against extreme weather conditions including high winds, ice loading, and salt fog exposure. All models are engineered to meet or exceed ANSI/TIA-222 standards for structural integrity, ensuring reliable operation even in the harshest environments. 'With the discontinuation of several long-standing antenna product lines in the market, organizations are actively seeking drop-in replacements that match or exceed the performance of their existing infrastructure,' said Jay Slomba, Director of Business Operations at TX RX Systems. 'Deepwave antennas are engineered to deliver uncompromising quality at a price point well below what customers are used to paying.' The Deepwave series is available now through the TX RX Systems website. Additional models will be released in the coming months to expand the range and cover even more application requirements. For more information or to request a quote, visit or contact a TX RX Systems Customer & Technical Support Specialist at sales@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data